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Abstract
Pulmonary hypertension (PH) is defined as an increase in mean pulmonary arterial pressure 
(mPAP) ≥ 25 mmHg at rest as assessed by right heart catheterization (RHC). The symptoms 
of PH are non-specific and mainly related to progressive right ventricular (RV) dysfunction. In 
some patients the clinical presentation may be related to mechanical complications of PH and 
the abnormal distribution of blood flow in the pulmonary vascular bed, include hemoptysis related 
to rupture of hypertrophied bronchial arteries. Hemoptysis is a serious complication that is rarely 
reported in patients with pulmonary arterial hypertension (PAH). Hemoptysis severity ranges from 
mild to very severe leading tosudden death. Hemoptysis are reported to be a terminal stage of 
a complication due to PAH with prevalence is variable, from 1% to 6%. Although the incidence 
is quite rare, the presence of recurrent hemoptysis in patients with pulmonary hypertension is 
a sign of poor prognosis. Bronchial artery embolization is suggested as an acute emergency 
procedure in the case of severe hemoptysis or as elective intervention in cases of frequent 
mild or moderate episodes. 
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Intisari
Hipertensi pulmonal (HP) didefinisikan sebagai peningkatan rerata tekanan arteri pulmonal ≥ 25 
mmHg saat istirahat yang diukur dengan kateterisasi jantung kanan (KJK). Gejala-gejala dari 
HP tidak spesifik dan terutama berhubungan dengan difungsi ventrikel kanan yang progresif. 
Pada beberapa pasien, presentasi klinis mungkin berhubungan dengan komplikasi mekanis 
HP dan distribusi aliran darah yang tidak normal pada pulmonary vascular bed, termasuk 
hemoptisis yang berhubungan dengan hipertrofi arteri bronkhialis. Hemoptisis merupakan 
komplikasi serius yang jarang dilaporkan pada pasien dengan hipertensi arteri pulmonal (HAP). 
Keparahan hemoptisis berkisar dari ringan sampai sangat berat yang menyebabkan kematian 
mendadak. Hemoptisis dilaporkan merupakan stadium terminal dari komplikasi HAP dengan 
prevalensi bervariasi, dari 1% sampai 6%. Meskipun insidensi sangat jarang, adanya hemoptisis 
berulang pada pasien dengan HP merupakan petanda prognosis yang buruk. Embolisasi arteri 
bronkhialis dilaporkan sebagai tindakan kegawatan pada kasus hemoptisis berat atau sebagai 
tindakan elektif pada kasus episode ringan atau sedang yang berulang.
INTRODUCTION
Pulmonary hypertension (PH) is a 
pathophysiological disorder that encompasses 
various clinical conditions and could be a 
complication of cardiovascular disease and 
respiration. Based on the 2015 ESC/ERS 
Guidelines for the diagnosis and treatment of 
pulmonary hypertension, pulmonary hypertension 
is defined as an increase in mean pulmonary 
arterial pressure (mPAP) ≥ 25 mmHg at rest, 
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with the assessment of right heart catheterization 
(RHC).1 Pulmonary Artery Hypertension (PAH) 
is one of the subtypes of PH characterized by 
pre-capillary pulmonary hypertension, defined as 
pulmonary artery wedge pressure (PAWP) ≤15 
mmHg and Pulmonal Vascular Resistance (PVR) 
> 3 Wood Unit (WU), in the absence of other 
causes of pulmonary pre-capillary hypertension, 
such as pulmonary hypertension associated with 
pulmonary disease, chronic thromboembolic 
pulmonary hypertension (CTEPH), or other rare 
diseases.1
Microscopically, PAH is characterized by 
intimal hyperplasia, hypertrophy of the tunica 
media, thickening of the tunica adventitia, and 
endothelial proliferation. The disease was first 
discovered by Dr. Ernst von Romberg in 1891.2,3 
The incidence of PAH is very rare, where in 
France the incidence is only 15 cases for every 
million people.2,3
Hemoptysis is a serious complication that is 
rarely reported in patients with pulmonary arterial 
hypertension (PAH). Hemoptysis is reported to be 
a terminal stage of a complication due to PAH. The 
incidence of hemoptysis in PAH patients remain 
uncertain and tend to be unreported. Similarly, the 
patho-mechanism of hemoptysis in PAH remains 
uncertain.4 Mortality associated with hemoptysis 
in PAH is influenced by multifactorial. Some 
evidence suggests that patients with PAH who are 
associated with congenital heart disease have a 
better prognosis for their hemoptysis complications 
than other PAH types. However, the underlying 
mechanisms of this condition remain unknown.4,5
CASE PRESENTATION
We reported the case of a 25-year-old 
woman who came to the Dr. Sardjito Hospital 
Emergency Hospital with a chief complaint of 
hemoptysis. On the day of admission, the patient 
complained of coughing up blood and shortness 
of breath. The blood was bright red with a total of 
about 400 mL. Complaints of fever, chest pain, 
back pain, nausea or vomiting are refuted. The 
patient then immediately goes to the Emergency 
Room of Dr. Sardjito Hospital.
Past medical history: The patient has 
had previous similar complaints and has been 
hospitalized several times in Sardjito Hospital. 
The patient was last hospitalized in Sardjito 
Hospital in November 2015 with a diagnosis 
Primary Pulmonary Artery Hypertension (PAH) 
high resistance non-reactive O2 test, observation 
of hemoptysis suspected to be associated with 
pulmonary hypertension. Patients received routine 
therapy with sildenafil 40 mg t.i.d, digoxin 0.25 mg 
q.i.d, codeine (if necessary), beraprost 20 mg t.i.d. 
furosemide 20 mg q.i.d. History of hypertension, 
diabetes mellitus, hormonal contraceptive use and 
family history with similar complaints are denied.
In physical examination, the general 
condition is sufficient, compos mentis mental state, 
with a slightly shortness of breath. The vital sign is 
blood pressure 90/70 mmHg, pulse 110 x/minute, 
respiratory rate 28 x/minute, body temperature: 
36.9o C and peripheral oxygen saturation is 92% 
(with oxygen nasal cannula 4 liters per minute). 
Head examination is within normal limits. Neck 
examination shows increased jugular venous (5+4 
cm H2O). Thechest examination shows symmetrical 
movement without any abnormality in inspection, 
palpation, percussion, and auscultation of the lung. 
Cardiac examination reveals cardiomegaly with 
RV heaving (+), 2nd heart sound waslouder, pan-
systolic murmurgrade 3/6 with punctum maximum 
atleft lower sternal border. Abdominal examination 
are within normal limits and there was no peripheral 
edema.
From the electrocardiography (ECG) 
examination showed sinus rhythm with heart 
rate 120x / minute, Right Axis Deviation (RAD), 
Right Ventricle Hypertrophy (RVH), Right Atrial 
Enlargement (RAE) (Figure 1). From the chest 
x-ray examination there is cardiomegaly (CTR: 
0.58) with aortosclerosis and bilateral pneumonia 
(Figure 2).
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From the laboratory examination shows 
hemoglobin level 10.6 g/dL, platelet count 417.000/
µL, and increased leukocyte count 22.950/µL with 
the dominance of segment (Segment: 82.8%, 
Lymphocyte 11.6%, Monocyte 5.1%). The blood 
chemistry shows BUN 10.5 mg/dL, creatinine 
0.79 mg/dL, Albumin 4.55 mg/dL, SGOT 24 U/L, 
SGPT 17 U/L, random blood glucose 111 mg/dL. 
Electrolyte examination showed the presence 
of hypokalemia with potassium level 2.9 mEq/
dL, sodium 136 mEq/dL, Chloride: 90 mEq/L. 
Examination of bleeding diastases within normal 
limits with PPT: 19.1 (control 15.2), APTT: 24.9 
(control 33.3), INR: 1.51.
Figure 1. The ECG showed Sinus Rhythm with 
heart rate 120 x/minute, Right Axis Deviation 
(RAD), Right Ventricle Hypertrophy (RVH), Right 
Atrial Enlargement (RAE)
Figure 2 .  The Chest  X-Rays showed 
cardiomegaly (CTR: 0.58) with aortosclerosis 
and bilateral pneumonia
From echocardiography examination 
shows RA and RV dilatation (LVIDs 29 mm, 
LVIDs 16 mm, LVPWd 6 mm, RA 49 mm, RV 37 
mm); Global LV systolic function normal with EF 
77%; LV diastolic dysfunction: relaxation type; 
Decreased of RV systolic function (TAPSE 14); 
IVS paradox (LV D-shaped). Mild MR, moderate 
TR (TVG 121 mmHg), PH severe (Figure 3).
From the Chest Computed Tomography 
examination showsa dilation of the pulmonary 
truncus with diameter ± 3.59 cm, dilatation of 
the right pulmonary artery with diameter ± 2.69 
cm, dilatation of the left pulmonary artery with 
diameter ± 2.51 cm, and dilatation of the bilateral 
pulmonary artery branches. The diameter of the 
pulmonary truncus is greater than the ascending 
aortic aorta; There is enlargement of the right 
atrium and the right ventricle. Conclusion: 
Dilatation of the pulmonary artery that supports 
the diagnosis of pulmonary hypertension (Figure 
4).
Patients have also performed right heart 
catheterization in the previous hospitalization 
(April 20, 2015), with results: Primary pulmonary 
hypertension. Pre O2 test: mPAP = 98 mmHg, 
Pulmonary Artery Resistance Index (PARI) = 
39. Post O2 test: mPAP = 99 mmHg,PARI = 35. 
Conclusion: primary pulmonary hypertension, 
high resistance, non reactive with O2 test.
Patients were diagnosed with primary 
pulmonary arterial hypertension non-reactive 
O2 test, observation of hemoptysis suspected 
to be associated with pulmonary hypertension, 
suspected Health Care-Associated Pneumonia 
(HCAP) andhypokalemia. The treatments were: 
sildenafil 40 t.i.d. mg, digoxin 0.25 mg q.i.d., 
furosemide 20 mg q.i.d., iloprost nebulizer 2.5 
mcg q.i.d., Aspar K 1 tablet q.i.d., intravenous 
ceftazidime 1 gr t.i.d., intravenous ciprofloxacin 
400 mgb.i.d..
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Figure 4. The Chest Computed Tomography examination showed dilatation of the pulmonary artery 





Figure 3. The Echocardiography showed RA and RV dilatation; Global LV systolic function 
normal with EF 77%; LV diastolic dysfunction: relaxation type; Decreased of RV systolic 
function; IVS paradox (LV D-shaped); Mild MR, moderate TR, PH severe 
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Figure 3. The Echocardiography showed RA and RV dilatation; Global LV systolic function normal 
with EF 77%; LV diastolic dysfunction: relaxation type; Decreased of RV systolic function; IVS paradox 
(LV D-shaped); Mild MR, moderate TR, PH severe
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Discussion
Diagnosis of pulmonary hypertension 
is established by taking a comprehensive 
look at clinical signs and symptoms, physical 
examination results, and the results of additional 
investigations. Examination results are used to 
confirm the hemodynamic criteria of Pulmonary 
Hypertension as well as to explain the etiology 
and severity of the disease.1 In accordance with 
the 2015 ESC/ERS Guidelines of pulmonary 
hyper tens ion,  d iagnosis  of  pu lmonary 
hypertension can be established if there is an 
increase in mean pulmonary arterial pressure 
(mPAP) ≥25 mmHg at rest, as measured by 
right heart catheterization (RHC). Clinically, 
Pulmonary Hypertension is grouped into 5 
subtypes, as shown in Table 1.1,6
Based on the 2015 ESC/ERS Guidelines 
of Pulmonary Hypertension, diagnosis of 
Pulmonary Hypertension is established by 
following the algorithm flow as shown in Table 1. 
Based on the algorithm flow of the ESC guideline, 
anamnesis and physical examination is the initial 
modality in diagnosing Pulmonary Hypertension. 
But often the disease at an early stage is 
usually asymptomatic. The disease usually 
progresses with symptoms that vary widely, 
ranging from mild to severe. Generally patients 
complain of shortness of breath that is getting 
worse, malaise, unproductive cough, fainting 
or syncope, peripheral edema and sometimes 
hemoptysis, which is rare in most patients. 
There is usually no symptom of orthopnea and 
paroxysmal nocturnal dyspnea.1,7
Physical  examinat ion is relat ively 
insensitive to make the diagnosis, but it can help 
to rule out the differential diagnosis. If on lung 
examination found wheezing and rales, should 
be considered the possibility of bronchial asthma, 
bronchitis or fibrosis. Rales as seen in congestive 
Table 1. Clinical Classification of Pulmonary Hypertension1
Source: Galie et al. (2015)
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heart failure shows left heart failure. Louder of 
2nd heart sounds in the pulmonary region can be 
found in nearly 90% of patients with advanced 
PH when right heart failure occurs. In addition, 
symptoms and signs such as gallop, jugular 
venous distention, liver or spleen enlargement 
or both, ascites or peripheral edema may be 
present.8
In this case report, the diagnosis of PH has 
generally followed the algorithm in the 2015 ESC/
ERS Guidelines of Pulmonary Hypertension. 
Nevertheless, there are some examinations that 
can not be done because of limited facilities and 
not routinely done in Dr. Sardjito Hospital, such 
as V/Q Scan Pulmonary examination, CT Scan 
Pulmonary Angiography, and genetic examination.
In accordance with the 2015 ESC/ERS 
Guidelines of Pulmonary Hypertension above, 
the diagnosis of PH requires a variety of 
additional investigations to definitively diagnose, 
exclude the differential diagnosis, and to 
determine the clinical classification of pulmonary 
hypertension.1. The investigations that may be 
used to confirm the diagnosis of pulmonary 
hypertension include:1,8
• Electrocardiography
• Chest X ray 
• Echocardiography
• Ventilation / Perfusion Lung Scan
• CT Pulmonary Angiography
• Right Heart Catheterization with / without 
pulmonary angiography
• Special / specific investigations
Electrocardiography (ECG)
On ECG examination patients with 
pulmonary hypertension sometimes show a 
right axis deviation and right atrial hypertrophy 
(RV) image. But often it is not significant. 
Chronic pulmonary emphysema can reduce the 
electrical voltage of the ECG and mask the signs 
of hypertrophy.9The ECGof the patient in this 
case report supports the presence of pulmonary 
hypertension, in which the ECG shows the 
presence of Right Axis Deviation (RAD), Right 
Ventricle Hypertrophy (RVH), and Right Atrial 
Enlargement (RAE)
Chest Radiography
Chest x-rays could show the presence 
ofpulmonary artery dilatation, underlying 
pulmonary disease, pulmonary perfusion defects 
(e.g. in patients with chronic thromboembolism), 
and also cardiomegaly.9 The chest X-ray of 
patients proposed in this case report supports the 
presence of pulmonary hypertension, wherein 
from chest X-ray image there is presence 
ofcardiomegaly (RV dilatation).
Echocardiography
In the 2015 ESC/ERS Guidelines of 
Pulmonary Hypertension, Echocardiography 
is recommended as a first-line non-invasive 
diagnostic test. Transthoracic echocardiography 
(TTE) is a non-invasive screening examination 
for pulmonary hypertension. Echocardiography 
examination may assess pulmonary artery 
pressure that equivalent to right ventricular 
systolic pressure, as long as there is no 
pulmonary outflow obstruction. The examination 
may also provide information about the causes of 
pulmonary hypertension including right and left 
ventricular dimensions and functions, vascular 
abnormalities, right ventricular ejection, left 
ventricular filling characteristics and pericardial 
effusion.1,7,9
The resu l ts  o f  echocard iography 
examination in this case report also support the 
diagnosis of pulmonary hypertension, which the 
results showed: RA and RV dilatation (LVIDs 29 
mm, LVIDs 16 mm, LVPWd 6 mm, RA 49 mm, RV 
37 mm); Global LV systolic function normal with 
EF 77%; LV diastolic dysfunction: relaxation type; 
Decreased of RV systolic function (TAPSE 14); 
IVS paradox (LV D-shaped). Mild MR, moderate 
TR (TVG 121 mmHg), PH severe.
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Cardiac Magnetic Resonance Imaging
Cardiac magnetic resonance imaging 
(CMRI) is not included in the recommended 
support modalities in the 2015 ESC/ERS 
Guidelines. However, CMRI examination can 
accurately measure the magnitude and function 
of the left and right ventricle. Examination of right 
ventricular function is important for prognosis 
and indicators of Pulmonary Hypertension. From 
MRI examination, it can be measured: function, 
stroke volume whether ≤ 25 mL/m2, diastolic 
final volume of ≥ 84 mL/m2, and end-diastolic 
ventricular volume ≤ 40 mL/m2.10,11
Right Heart Catheterization
Not al l  of pat ients suspected with 
pulmonary hypertension should undergo 
invasive examination such as right heart 
catheterization (RHC). Some patients are 
adequately diagnosed by non-invasive methods 
such as echocardiography. However, if the 
diagnosis still cannot be enforced, then the 
patient needs to undergo invasive examination 
such as RHC. Right heart catheterization is 
performed to confirm the diagnosis of PAH, 
assess the degree of severity, and assess the 
vasodilatation response of the drug or high 
concentration oxygen. In addition, pulmonary 
arteriography examination may also show the 
presence of thromboembolic disease.1,12
In this case report, the result of RHC of the 
patient support the diagnosis of pulmonary arterial 
hypertension, where the mean pulmonary arterial 
pressure (mPAP) = 98 mmHg, pulmonary artery 
wedge pressure (PAWP) value = 11 mmHg and 
Pulmonary Artery Resistance Index (PARI) = 39. 
This value corresponds to the diagnostic criteria 
of Pulmonary Artery Hypertension (PAH). In the 
patients presented in this case report, all ofthe 
examination led to a diagnosis of Pulmonary 
Artery Hypertension. This is based on signs and 
symptoms, the results of physical examination 
and various investigations that have been done 
such as ECG, chest x-ray, echocardiography, and 
especially the results of the RHC examination.
Pulmonary Artery Hypertension (PAH) 
is one of the subtypes of PH characterized by 
pre-capillary pulmonary hypertension, defined as 
pulmonary artery wedge pressure (PAWP) ≤ 15 
mmHg and Pulmonal Vascular Resistance (PVR) 
> 3 Wood Unit (WU), in the absence of other 
causes of pulmonary pre-capillary hypertension, 
such as pulmonary hypertension associated with 
pulmonary disease, chronic thromboembolic 
pulmonary hypertension (CTEPH), or other rare 
diseases.1
Pathophys io logy o f  Pu lmonary  Ar tery 
Hypertension
Pulmonary arterial hypertension (PAH) is 
a serious disease in which there is progressive 
pulmonary vascular resistance that can lead to 
right ventricular failure and death. Microscopically, 
PAH is characterized by intimal hyperplasia, 
hypertrophy of the tunica media, thickening of the 
tunica adventitia, and endothelial proliferation. In 
PAH there is an increase in pulmonary vascular 
resistance resulting in decreased right ventricular 
function due to afterload. The main cause of 
increased vascular resistance is remodeling due 
to excessive cell proliferation and decreased 
apoptosis. In addition, vasoconstriction plays an 
important role in about 20% of patients.3,10
In PAH occurs various pathological 
changes such as endothelial dysfunction, 
decreased apoptosis or proliferation ratio of 
pulmonary artery smooth muscle cells, tunica 
intima and media thickening, tunica adventitia 
abnormalities, and activation of excessive 
metalloproteases adventitious that similar 
to cancer and atherosclerosisprocess. In 
PAH, production of vasoconstrictors such as 
endothelin and thromboxane by endothelium 
increases, but on the other hand there is a 
decrease in the production of vasodilators such 
as prostacyclin.3,13
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In addition, in the lumen of a patient’s blood 
vessel with PAH, an elevated plasma serotonin 
level was found. Serotonin can stimulate the 
proliferation of smooth cardiac muscle cells and it 
is an important sign in the pathogenesis of PAH. 
Nitric oxide (NO) produced in the endothelial is a 
vasodilator that will inhibit platelet activation and 
vascular smooth muscle cell proliferation formed 
from three nitric oxide isoforms (NOs / S / NOS3). 
However, the role of NO in PAH pathophysiology 
remains unclear. Pulmonary arterial hypertension 
has a poor prognosis and high mortality, despite 
adequate treatment.13,14
Clinically, in pulmonary arterial hypertension 
(PAH), there are several groups of patients with 
increased pulmonary artery pressure where the 
underlying cause is unclear. In this group, there 
was an increase in pulmonary arterial pressure but 
without an increase in pulmonary arterial wedge 
pressure. In this patient, the diagnosis of primary 
pulmonary hypertension is established clinically. 
From the clinical clustering of primary pulmonary 
hypertension, there are 3 different histopathologic 
features: 1) plexogenic pulmonary arteriopathy, 
2) recurrent pulmonary thromboembolism, and 3) 
veno-occlusive pulmonary disease.7
In primary pulmonary hypertension type 
plexogenic, characterized initially by pulmonary 
artery vasoconstriction and tunica media 
hypertrophy. Next will be followed by the 
proliferation of tunica intima, including the 
development of plexiform lesions. In recurrent 
pulmonary Thromboembolism type, it is 
characterized by the presence of arterial thrombus 
of varying sizes that involving pulmonary artery 
with microscopic size. Thrombus in recurrent 
pulmonary thromboembolism type, can be 
derived from embolism or in situ development. 
While the histopathological features of 
pulmonary hypertension withveno-occlusive 
pulmonary disease type, are characterized by 
obstructive lesions of the pulmonary venous 
and venules. Clinical presentation of the above 
three pathological types can be very similar, 
where the definitive diagnosis is confirmed by 
histopathological examination of lung tissue 
taken by biopsy or necropsy.7
Pathophysiology of Hemoptysis in Pulmonary 
Artery Hypertension
Hemoptysis is defined as a coughing of 
blood whose source originates from the lungs 
or bronchial tubes, as a result of pulmonary or 
bronchial haemorrhage. Hemoptysis is divided 
into massive and non-massive based on the 
coughed blood volume. However, there is no 
Table 2. Differential Diagnosis of Hemoptysis15
Source: Badner, JL &Pachner RW. 200515
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uniform definition for the classification. Some 
literature defined hemoptysis as non-massive if 
the coughed blood volume is ≤ 200 mL per day. In 
general, the differential diagnosis of hemoptysis 
could be seen in table 2.15
Hemoptysis is a serious complication that 
is rarely reported in patients with pulmonary 
arterial hypertension (PAH). Hemoptysis is 
reported to be a terminal stage of a complication 
due to PAH. The incidence of hemoptysis in 
PAH patients remains uncertain and tends to be 
unreported. Similarly, the patho-mechanism of 
hemoptysis in PAH remains uncertain.4
Pulmonary arterial hypertension (PAH) is 
a pathological condition whose primary cause 
originates from pulmonary circulation, where 75% 
of patients with PAH show evidence of bronchial 
artery hypertrophy on CT-Scan examination. The 
number of dilated bronchial arteries increases 
with increasing severity of PAH. These data 
suggest the hypothesis that the presence of 
bronchial artery hypertrophy increases the risk 
of hemoptysis in PAH patients.11
Hemoptysisis reported in 6% of PAH 
patients followed for 10 years in Poland. Other 
data from France suggest that the incidence of 
hemoptysis in PAH patientsoccurs in 1 for every 
137 patients each year. Aside from bronchial 
artery hypertrophy, hemoptysis in patients 
with PAH can be derived from rupture of the 
pulmonary artery. There have been various 
reports of hemoptysis occurrence in patients 
with pulmonary arterial aneurysm or pseudo-
aneurysms.2,16
PAH is associated with a progressive 
dilatation of the pulmonary artery and an 
increase in intraluminal pressure, wherein 
the dilatation of the existing pulmonary artery 
will result in an increased risk of the patient 
to experience pulmonary artery rupture and 
followed by hemoptysis. In addition, it was found 
that in about 25% of patients with Pulmonary 
Artery Hypertension (PAH), there was a genetic 
mutation in the Bone Morphogenetic Protein 
type 2 Receptor (BMPR2) gene . The BMPR2 
gene plays a role in regulating the growth, 
differentiation and apoptosis of epithelial and 
mesenchymal cells. The BMPR2 gene also plays 
a role in responding to the presence of trauma to 
cells. Damage or mutations in the BMPR2 gene 
causing decreased blood vessel stability. As a 
result, PAH patients with mutations in the BMPR2 
gene are likely to have unstable pulmonary and 
bronchial blood vessels, thus increasing the 
risk of rupture of the blood vessels resulting in 
hemoptysis.5,4
In patients presented in this case report, 
recurrent episodes of hemoptysis make the 
patient several times hospitalized. Patients have 
been screened for tuberculosis from sputum 
examination, Chest x-ray, and Thorax CT-Scan to 
exclude the possibility of hemoptysis-associated 
tuberculosisor malignancy. From the results 
of the examination was not found evidence of 
tuberculosis infection and lung or respiratory 
malignancy.
 
Treatment of Hemoptysis Associated with 
Pulmonary Hypertension
In the 2015 ESC/ERS Guidelines for 
pulmonary hypertension, an algorithm of 
pulmonary arterial hypertension therapy is 
presented. Currently, several studies for the 
treatment of pulmonary hypertension have 
been performed, such as class of vasodilators, 
prostanoids, nitric oxide, phosphodiesterase 
inhibitors, endothelin receptor antagonists and 
anti-coagulants treatment.1,3
Based on existing studies, it was found 
that in patients with idiopathic pulmonary 
arterial hypertension who responded well to 
acute vasodilator (oxygen test) during right 
heart catheterization, only a small proportion 
responded well to calcium channel blockers. 
Calcium-blocking drugs have been studied in 
patients with pulmonary hypertension, including 
54  
Nugraha et al., 2017
Copyright©2013. Jurnal Perikanan (Journal of Fisheries Sciences) All Right Reserved
nifedipine, diltiazem and amlodipine. Selection 
of calcium-blocking drugs was based on the 
patient’s initial heartbeat, whereas in patients with 
relative bradycardia, nifedipine and amlodipine 
were selected, whereas patients with relative 
tachycardia were given treatment options with 
diltiazem.17Rich et al., 1992 studied the use of 
Calcium Blockers in PAH patients 95% of patients 
survived for 5 years. Use of verapamil should be 
avoided because of its negative inotropic effect. 
The use of the above drug causes significant 
adverse events such as severe hypotension that 
can be life-threatening to the patient, requiring 
rigorous monitoring of patients’ hemodynamics.18 
In patients reported in this case report were not 
treated with a calcium-blocker group because 
from an acute vasodilator test (oxygen test) 
showed non-reactive results.
Bosentan is included in the class of 
endothelin receptor antagonists (ERAs). 
Bosetan is used in medicine because of much 
evidence about the role of endothelin-1 in the 
pathogenesis of pulmonary hypertension. 
Endothelin-1 is a potent vasoconstrictor and 
a smooth muscle mitogen which contributes 
to increased vascular tone and pulmonary 
vascu lar  hyper t rophy assoc ia ted wi th 
pulmonary hypertension.19 In patients with 
PAH, elevated endothelin-1 and its plasma 
products were obtained. It is associated 
with the severity of the disease. The first 
randomized, double-blind, placebo-controlled, 
and multicenter study with bosentan 62.5 mg 
twice daily for the first four weeks, continued 
to a dose of 125 mg twice daily. Patients in the 
study were severe idiopathic PAH or PAH with 
scleroderma who experienced heart failure in 
accordance with functional categories Class III 
& IV according to NYHA. The use of bosentan, 
showed improvement in the heart index, 
decreased the median value of pulmonary 
artery pressure and improved the category of 
heart failure according to NYHA.19
Sildenafil, including the phosphodiesterase 
inhibitor group, is a specific phosphodiesterase 
type 5 inhibitor. Formerly known as a drug used 
for erectile dysfunction. The study of 278 patients 
with idiopathic PAH and PAH with connective 
tissue abnormalities or with corrected cardiac 
congenital abnormalities, using placebo or 
sildenafil (20.40 and 80 mg) administered orally 
three times daily for 12 weeks. In the group 
using sindenafil there was a decrease in mean 
artery pulmonary pressure (mPAP).20 The FDA 
approved sildenafil to decrease pulmonary artery 
pressure in PAH at a dose of 20 mg three times 
daily. Higher doses can mPAP, but high doses 
in the long term cause side effects dizziness, 
headache, epistaxis, nausea and vomiting.21
Hemoptysis is known to be one of the 
complications of pulmonary hypertension. 
Although the incidence is quite rare, the presence 
of recurrent hemoptysis in patients with pulmonary 
hypertension is a sign of poor prognosis. 
Hemoptysis is generally a complication of 
pulmonary hypertension, especially subtype: 
hereditary pulmonary hypertension, pulmonary 
hypertension associated with congenital heart 
disease and chronic thromboembolic pulmonary 
hypertension. The severity of hemoptysis in 
patients with pulmonary hypertension varies from 
mild to severe which can result in sudden death. 
The prevalence of hemoptysis complication in 
patients with pulmonary hypertension varies 
from 1% to 6%.4,5
Based the 2015 ESC/ERS Guidelines 
for pulmonary hypertension, Bronchial artery 
embolization is recommended as an immediate 
emergency procedure in patients with severe 
hemoptysis pulmonary hypertension, or as 
an elective intervention in mild-to-moderate 
hemoptysis wi th a f requency episode. 
Anticoagulant therapy in patients with pulmonary 
hypertension with hemoptysis episodes should 
be postponed for a time.1In this case report, 
patients were not undergoing bronchial artery 
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embolization procedures, because during 
hospitalization the hemoptysis complaints 
improved with pharmacological therapy.
Prognosis of Hemoptysis Associated with 
Pulmonary Hypertension
The prognosis of PAH is usually worse 
because it is generally caused by other diseases. 
Usually, patients realize if they have pulmonary 
hypertension after the clinical symptoms appear, 
which that means the patient is already in an 
advanced stage. If it was diagnosed earlier, the 
prognosis will be better, at least in terms of reducing 
symptoms. Hemoptysis is known to be one of 
the complications of pulmonary hypertension. 
Although the incidence is quite rare, the presence 
of recurrent hemoptysis in patients with pulmonary 
hypertension is a sign of poor prognosis.4,5
Conclusion
It has been reported 25-year-old female 
patients with non-reactive O2 test of Primary 
Pulmonary Hypertension and observation of 
hemoptysis suspected to be associated with 
pulmonary hypertension. Hemoptysis is a serious 
complication that is rarely reported in patients 
with pulmonary arterial hypertension (PAH). 
Hemoptysis are reported to be a terminal stage 
of a complication due to PAH. The incidence of 
hemoptysis in PAH patients remains uncertain 
and tends to be unreported. Similarly, the patho-
mechanism of hemoptysis occurrence in PAH 
remains uncertain. Although the incidence is 
quite rare, the presence of recurrent hemoptysis 
in patients with pulmonary hypertension is a 
sign of poor prognosis. Based on the 2015 ESC/
ERS Guidelines for pulmonary hypertension, 
Bronchial artery embolization is recommended as 
an immediate emergency procedure in patients 
with severe hemoptysis pulmonary hypertension, 
or as an elective intervention in mild-to-moderate 
hemoptysis with a frequency episode.
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